WP6 assists in complying with relevant legislation and ethical guidelines. WP6 continuously monitors the implementation of the measures to protect data and privacy that were developed by the initial HARMONY action. In addition, WP6 investigates if HARMONY PLUS-specific activities call for modifications to the existing legal and ethical framework of HARMONY and the informed consent form. WP6 will collaborate with other IMI BD4BO projects [LINK] and with EDHEN [LINK].
IECSCYL, Hospital La Fe, Charite, GMV, UNIBO, LeukaNET, EHA, Synapse, Bayer, Pfizer.
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
